Sitemap

Posts:

• Category: articles-2015 (1)
  • 09 Dec 2015 – Q&A Proactive Investors
• Category: articles-2016 (9)
  • Zelda Therapeutics to Test Formulations against Pancreatic Cancer
  • Company Secretary Appointment
  • Sleep disorder clinical trials update
  • Zelda Therapeutics Enters Into Collaboration Agreement with Prestigious Telethon Kids Institute
  • Significant Anti-Cancer Effect Observed in Pre-Clinical Studies
  • Zelda Expands Intellectual Property Portfolio
  • Zelda Therapeutics debuts on ASX
  • Investor Presentation – Nov 2016
  • 19 Jan 2016 – Q&A Proactive Investors
• Category: articles-2017 (25)
  • Meet Kara: Medical Cannabis & Autism
  • ‘Medical Cannabis: The current and future investment market’ – by Dr. Stewart Washer
  • Medical Cannabis for Autism
  • ASX Announcement: Successful Results in Autism Observation Trial
  • ASX Announcement: Update on Research Programme in Chile
  • ASX Announcement: Zelda’s Annual Report for the Year Ended 30 June 2017
  • ASX Announcement: Company Presentation on 2017 Half Year Activities
  • CY Half Year Review 2017
  • Cannabis in South America
  • Zelda featured in Australian Financial Review
  • ASX Announcement: Zelda Expands Breast Cancer Research Collaboration with Complutense
  • Breast Cancer and Cannabis Treatments
  • ASX Announcement: Zelda enters strategic agreement with Knop Laboratories
  • Dr. Stewart Washer talks with Health Professional Radio about recent pre-clinical breast cancer results
  • Positive results from pre-clinical breast cancer studies (GIF)
  • ASX Announcement: Follow on studies confirm anti-cancer effect in human breast cancer
  • Medical Cannabis Therapy for Insomnia
  • How medical cannabis can help insomnia?
  • Update #2: Our Research Focus (GIF)
  • CannaInvestor Webcast Feb/March Issue
  • Update #1 by Patty Washer
  • What’s all the Fuss About Medical Cannabis?
  • CANNAINVESTOR Magazine: Zelda Therapeutics Feature Article
  • Interview with Dr Stewart Washer of Zelda Therapeutics – Part 2
  • Interview with Dr Stewart Washer of Zelda Therapeutics – Part 1
• Category: articles-2018 (7)
  • Prescription Opioid Crisis
  • ASX Announcement: Zelda Partners St Vincent’s Hospital on Opioid Reduction Study
  • VIRIATHUS RESEARCH REPORT
  • Viriathus Research Report
  • PAEDIATRIC BRAIN CANCER RESEARCH UPDATE
  • ‘Medicinal cannabis: Australia isn’t as progressive as it may seem” – By Dr. Stewart Washer
  • ASX Announcement: Shares Begin Trading in the USA on the OTCQB Venture Market
• Category: articles-2019 (6)
  • CFN Media Interviews Zelda Therapeutics at New West Summit
  • Shareholder Briefing Invitation, Perth
  • Forbes Article – Mara Gordon: Aunt Zelda’s, For Every Household
  • Zelda Therapeutics – Pioneering Australian Medicinal Cannabis Research
  • Zelda Therapeutics to outline cannabinoid-based strategy at Proactive CEO Sessions
  • March 2019 Quarterly Report
• Category: articles-2020 (22)
  • 18 Minutes with Zelira Therapeutics – 180 Markets
  • The West Australian – Perth family describes their desperation when they sought cannabis for autistic, suicidal son
  • OPINION | Reform should be driving protection for medicinal cannabis patients
  • Investor buzz around cannabis stocks with new treatments
  • Zelira Therapeutics (ASX:ZLD) launches Zenivol in Australia
  • Zelira Therapeutics’ insomnia treatment gets TGA tick
  • Zelira Therapeutics launches Zenivol™ product in Australia after TGA adds to Special Access Scheme
  • Medicinal cannabis trial could help retired AFL players manage chronic pain
  • Zelira Therapeutics forms subsidiary to launch hemp-derived oral care products in the USA
  • Proactive – Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers
  • Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers
  • Zelira Therapeutics MD shows faith in medical cannabis strategy with placement participation
  • Proactive – Three medical cannabis companies in focus at Proactive’s webinar on August 11
  • Starts at 60 – Suffer from chronic pain? Medicinal cannabis could be the answer
  • TechInvest – Zelira obtains key data in cannabis dose escalation study
  • The Market Herald – Zelira Therapeutics (ASX:ZLD) confirms ZTL-103 is safe and well-tolerated
  • Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints
  • Stockhead – Pot stock Zelira Therapeutics successfully passes another Phase I clinical trial
  • Benzinga Article: A Medicinal Cannabis Company That’s Conducting Clinical Research On Autism, Insomnia, And More
  • Q&A with Osagie Imasogie, Chairman, Zelira Therapeutics: Zelira Phase 1b/2a Insomnia Clinical Trial Results
  • Biotech Daily – Zelira: Marijuana ZLT-101 ‘Effective For Insomnia’
  • Stockhead – Dr Boreham’s Crucible: Zelira’s share price could wake up once sales of its pot-based insomnia drug start
• Category: news (25)
  • 18 Minutes with Zelira Therapeutics – 180 Markets
  • Cantor Fitzgerald Hosts Fireside Chat with Zelira Therapeutics
  • Medicinal cannabis trial could help retired AFL players manage chronic pain
  • Sequoia Initiation Research Report, 19 August 2020
  • Proactive – Three medical cannabis companies in focus at Proactive’s webinar on August 11
  • Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints
  • Stockhead – Pot stock Zelira Therapeutics successfully passes another Phase I clinical trial
  • Zelira’s Oludare Odumosu, Managing Director USA speaking at More Than A Moment virtual event
  • Dr Richard Hopkins, Zelira Therapeutics – 3AW Chronic Pain Interview
  • 9 Today – Sleep Drug Jackpot: Is Cannabis oil the answer to insomnia?
  • Zelira’s Dr Richard Hopkins, Managing Director – ex USA will be presenting on the 2 June, 2pm AEST at the 2020 Finance News Network CEO Showcases
  • Benzinga Article: A Medicinal Cannabis Company That’s Conducting Clinical Research On Autism, Insomnia, And More
  • Dr Richard Hopkins, Zelira Therapeutics – Triple M Great Southern WA
  • Cannaweek Podcast, 05 May 2020
  • Review of Zelira’s Insomnia Clinical Trial by Paul Mavor, Health House International Pty Ltd
  • Q&A with Osagie Imasogie, Chairman, Zelira Therapeutics: Zelira Phase 1b/2a Insomnia Clinical Trial Results
  • Zelira’s Medicinal Cannabis Insomnia Clinical Trial on Channel 10 News First
  • Biotech Daily – Zelira: Marijuana ZLT-101 ‘Effective For Insomnia’
  • Investor Teleconference: Insomnia Trial Meets Primary and Secondary Endpoints
  • Stockhead – Dr Boreham’s Crucible: Zelira’s share price could wake up once sales of its pot-based insomnia drug start
  • CFN Media Interviews Zelda Therapeutics at New West Summit
  • Autism Symposium
  • Forbes Article – Mara Gordon: Aunt Zelda’s, For Every Household
  • Zelda Therapeutics – Pioneering Australian Medicinal Cannabis Research
  • Zelda Therapeutics to outline cannabinoid-based strategy at Proactive CEO Sessions
• Category: report (2)
  • Sequoia Initiation Research Report, 19 August 2020
  • Viriathus Research Report, 13 September 2018
• Category: Uncategorized (1)
  • Zelira Transaction Investor Teleconference and Q&A (audio)
• Category: video-2020 (4)
  • Dr Richard Hopkins, Zelira Therapeutics – 3AW Chronic Pain Interview
  • 9 Today – Sleep Drug Jackpot: Is Cannabis oil the answer to insomnia?
  • Dr Richard Hopkins, Zelira Therapeutics – Triple M Great Southern WA
  • Cannaweek Podcast, 05 May 2020

Archives:

• December 2020 (1)
• November 2020 (2)
• October 2020 (1)
• September 2020 (6)
• August 2020 (5)
• July 2020 (5)
• June 2020 (3)
• May 2020 (4)
• April 2020 (5)
• March 2020 (1)
• October 2019 (2)
• June 2019 (1)
• May 2019 (3)
• April 2019 (1)
• January 2019 (1)
• November 2018 (2)
• September 2018 (2)
• June 2018 (1)
• February 2018 (1)
• January 2018 (1)
• December 2017 (1)
• September 2017 (4)
• August 2017 (5)
• July 2017 (2)
• June 2017 (4)
• May 2017 (3)
• March 2017 (4)
• January 2017 (2)
• December 2016 (4)
• November 2016 (4)
• January 2016 (1)
• December 2015 (1)